论文部分内容阅读
分析胺碘酮在不同的CYP2C9和VKORC1分型患者对华法林的抗凝作用的影响。纳入从2008年9月至2009年11月某三甲医院应用华法林的入院患者,收集患者一般信息、合并用药及其他临床相关数据,检测患者VKORCl和CYP2C9基因型;比较使用或未使用胺碘酮治疗患者抗凝稳定期INR值及华法林用量,纳入基因分型进行华法林/胺碘酮相互作用的亚组分析。结果未发现胺碘酮应用患者华法林稳定期用量和INR值的统计学差异,基因型亚组差异无统计学意义。这说明院内短期合并使用胺碘酮患者对华法林稳定剂量和INR值无显著影响。
Analysis of amiodarone in different CYP2C9 and VKORC1 typing warfarin on anticoagulant effects. Included hospitalized patients with warfarin in a top three hospital from September 2008 to November 2009 and collected general patient information, combined medication and other clinically relevant data to detect the patient's VKORCl and CYP2C9 genotypes; compared with or without the use of amine iodine The anticoagulant stability INR value and warfarin dosage in the keto-treated patients were included in the genotyping subgroup analysis of the warfarin / amiodarone interaction. The results did not find the application of amiodarone in patients with stable warfarin dosage and INR value of the statistical differences in genotypic subgroup differences were not statistically significant. This shows that short-term hospital use of amiodarone in patients with warfarin stable dose and INR no significant effect.